Lu Daopei Medical Group were invited to participate in the 2019 “the Belt and Road” Blood Elite Meeting National Launch Conference

The 2019 “the Belt and Road” Blood Elite Meeting was held in Suzhou on February 16th. The meeting was hosted by the First Affiliated Hospital of Suzhou University and Academician Ruan Changgeng and Professor Wu Depei. With the invitation of the organizing committee, hematology experts Lu Yue, Zhao Yanli, Sun Ruijuan, and Zhang Jianping from Lu Daopei Medical Group attended the meeting. The CEO of Lu Daopei Medical Group Lu Yang gave a report “Exploring the value growth of blood specialist hospitals”.

Lu Daopei Medical Group^TM is one of the most active hematopoietic stem cell transplantation centers in the world. In 2018, there were 773 cases of transplantation, and accumulated the completion of 5,071 cases of transplantation. Mr. Lu Yang, the CEO of the Group, summarized the development experience of the blood specialist hospital from four aspects: “Value orientation, Value shaping, Value culture and Value inheritance”.

1.   Value orientation: The development of the group is divided into three stages: “exploitation period, cultivation period and challenge period”. People in Dao Pei hospital adhered to the core medical value for 18 years, from cultivating the team, to technological innovation.

2.   Value shaping is the process of discipline construction. Lu Daopei Medical Group^TM has built the core competitiveness of “technology + service” from eight aspects, focusing on the “five-year whitening plan” and “six major” service system.

3.   Value culture: Building a cohesive team and organization is the internal driving force for hospital development. Value culture includes: learning organization, quality management system that pursues zero defects, and enterprising spirit of patient satisfaction and social respect, revealing that value culture is an important source of employee pride.

4. Value inheritance: From the successful allogeneic bone marrow transplantation in 1964 by Lu Daopei, and the continuous progress in transplantation technology and CAR-T technology in 2018, the data of Dao Pei showed that as of the end of 2018, AML (n =1240), ≥CR2 patients achieved an overall survival rate of 73.0%, and the overall survival rate of patients with non-remission status was 43.0%; in ALL (n=1082), CR1, ≥CR2, no remission, the overall survival rate of three different group before transplantation was 75.0%, 60.0%, 30.0%; the overall survival rate of AA (n=230) was 80.0%, and the overall survival rate of MDS (n=137) was 77.9%.

Oral Report of the 60th American College of Hematology (ASH) Lu Daopei Hospital in 2018, "Study on the Safety and Efficacy of CD-19 CAR-T Cell Therapy for Multiple Groups of High-risk Relapsed and Refractory B-ALL Patients", Academic Report Selected as 2019 high light. CAR-T technology has sought a remission opportunity for patients with refractory/relapsed acute lymphocytes, opening up a new channel for bridging transplants to achieve better disease-free survival, and bringing new hope to those refractory/relapsed patients.

Summary: The rapid development path and achievements of Lu Daopei Medical Group are rooted in four points: loyalty to social values, loyalty to innovation value, loyalty to talent value, and loyalty to technology value.